The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Iacobaeus, Ellen ^a   Amoudruz, Petra ^a   Ström, Mikael ^a   Khademi, Mohsen ^a   Brundin, Lou ^a   Hillert, Jan ^a   Kockum, Ingrid ^a   Malmström, Vivianne ^a   Olsson, Tomas ^a   Tham, Emma ^b   Piehl, Fredrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; NATALIZUMAB; VASCULOTROPIN A;

ALLELE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; FEMALE; FLOW CYTOMETRY; GENETICS; MALE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION;

ADULT; AGED; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79955790798     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019138     Document Type: Article

References (46)

1. Compston A, Coles A, (2008) Multiple sclerosis. Lancet 372: 1502-1517.
2. Eriksson M, Andersen O, Runmarker B, (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9: 260-274.
3. Martinelli Boneschi F, Rovaris M, Capra R, Comi G, (2005) Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev pp. CD002127.
4. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98-108.
5. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249: 1088-1097.
6. Lublin FD, Reingold SC, (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
7. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, et al. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73: 2003-2010.
8. Salzer J, Svenningsson A, Sundstrom P, (2010) Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 16: 287-292.
9. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, et al. (2010) Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133: 1602-1611.
10. Rosenstein JM, Krum JM, (2004) New roles for VEGF in nervous tissue-beyond blood vessels. Exp Neurol 187: 246-253.
11. Zacchigna S, Lambrechts D, Carmeliet P, (2008) Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 9: 169-181.
12. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131-138.
13. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, et al. (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23: 237-243.
14. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429: 413-417.
15. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, et al. (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25: 283-290.
16. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, et al. (2005) Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8: 85-92.
17. Lambrechts D, Poesen K, Fernandez-Santiago R, Al-Chalabi A, Del Bo R, et al. (2008) Meta-analysis of VEGF variations in ALS: increased susceptibility in male carriers of the -2578AA genotype. J Med Genet.
18. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP, (2009) VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 283: 66-68.
19. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ, (2002) Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61: 914-925.
20. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N, (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13: 554-573.
21. Su JJ, Osoegawa M, Matsuoka T, Minohara M, Tanaka M, et al. (2006) Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 243: 21-30.
22. Tham E, Gielen AW, Khademi M, Martin C, Piehl F, (2006) Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand J Immunol 64: 609-622.
23. Hamzaoui K, Ayed K, Hamza M, Hamzaoui A, (2009) VEGF and mRNA VEGF expression in CSF from Behcet's disease with neurological involvement. J Neuroimmunol 213: 148-153.
24. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
25. Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, et al. (2009) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72: 1322-1329.
26. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, et al. (2007) Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39: 1108-1113.
27. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
28. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, et al. (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23: 644-645.
29. Purcell S, Cherny SS, Sham PC, (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-150.
30. Kivisakk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, et al. (2009) Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72: 1922-1930.
31. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P, (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89: 607-648.
32. Vogt J, Paul F, Aktas O, Muller-Wielsch K, Dorr J, et al. (2009) Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol 66: 310-322.
33. Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pollinger B, Schnell C, et al. (2010) Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation 7: 95.
34. Croll SD, Ransohoff RM, Cai N, Zhang Q, Martin FJ, et al. (2004) VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol 187: 388-402.
35. Manoonkitiwongsa PS, Schultz RL, McCreery DB, Whitter EF, Lyden PD, (2004) Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J Cereb Blood Flow Metab 24: 693-702.
36. Kirk SL, Karlik SJ, (2003) VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 21: 353-363.
37. Mor F, Quintana FJ, Cohen IR, (2004) Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 172: 4618-4623.
38. Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pollinger B, Schnell C, et al. Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation 7: 95.
39. Then Bergh F, Dayyani F, Ziegler-Heitbrock L, (2004) Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol 146: 176-188.
40. Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, et al. (2001) Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124: 2169-2176.
41. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL, (1997) Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 94: 599-603.
42. Farez MF, Quintana FJ, Gandhi R, Izquierdo G, Lucas M, et al. (2009) Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat Immunol 10: 958-964.
43. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, et al. (2006) Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5: 343-354.
44. Lopez-Diego RS, Weiner HL, (2008) Novel therapeutic strategies for multiple sclerosis-a multifaceted adversary. Nat Rev Drug Discov 7: 909-925.
45. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, et al. (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13: 260-264.
46. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, et al. (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34: 383-394.